Compare EWTX & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | IRTC |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 2021 | 2016 |
| Metric | EWTX | IRTC |
|---|---|---|
| Price | $34.09 | $113.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $39.00 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 1.3M | 491.4K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | N/A | $19.60 |
| Revenue Next Year | N/A | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $12.31 | $101.75 |
| 52 Week High | $40.77 | $210.01 |
| Indicator | EWTX | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 49.42 |
| Support Level | $28.27 | $111.37 |
| Resistance Level | $35.00 | $126.41 |
| Average True Range (ATR) | 2.20 | 5.86 |
| MACD | -0.22 | 0.58 |
| Stochastic Oscillator | 29.32 | 53.92 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.